v3.26.1
Summary of Significant Accounting Policies and Recent Accounting Standards (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2024
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Dec. 31, 2024
Aug. 31, 2024
Product Information [Line Items]                
Deposit money market           $ 10,000    
Restricted cash $ 700,000     $ 700,000        
Cash and cash equivalents 2,168,000 $ 5,825,000 $ 9,521,000 2,168,000 $ 5,825,000 4,088,000 $ 9,521,000  
Research and development expense 2,000 14,000   $ 5,000 $ 33,000 $ 38,000 $ 7,166,000  
Number of Options, Outstanding, Balance       811,693 952,276 416,446,000 968,419,000  
Eos SENOLYTIXS Inc [Member]                
Product Information [Line Items]                
Cash and cash equivalents 974,756   $ 974,756    
Research and development expense $ 1,138,522 $ 3,375 $ 8,970 $ 1,587,705 $ 26,600 $ 35,225    
Number of Options, Outstanding, Balance     137,815     683,990    
Letter of Credit [Member]                
Product Information [Line Items]                
Restricted cash     $ 1,421,000       $ 1,421,000 $ 1,400,000
Revenue from Contract with Customer Benchmark [Member] | Customer Concentration Risk [Member] | Two Customers [Member]                
Product Information [Line Items]                
Concentration risk percentage             100.00%